ZZL-7

ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD). In Vitro ZZL-7 (1.0 μM; or 2 h) incubation of the cultured 293T cells transfected with nNOS and SERT, significantly decreases the SERT-nNOS complex level. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time . Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment . ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SERT-Cre mice Dosage: 10 mg/kg Administration: i.p.; once Result: Significantly increased firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. Form:Oil

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet